vimarsana.com
Home
Live Updates
Novartis Pharma AG: New Kisqali data shows consistent overal
Novartis Pharma AG: New Kisqali data shows consistent overal
Novartis Pharma AG: New Kisqali data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer
Data from the MONALEESA Phase III program provide further evidence of the unique profile of Kisqali, the CDK4/6 inhibitor with the longest reported median overall survival (OS) in HR+/HER2- metastatic
Related Keywords
Norway ,
San Antonio ,
Texas ,
United States ,
New Jersey ,
Barcelona ,
Comunidad Autonoma De Cataluna ,
Spain ,
East Hanover ,
America ,
American ,
Isabella Zinck ,
Thomas Hungerbuehler ,
Susanne Schaffert ,
Ashley Buford ,
Clin Onc ,
Samir Shah ,
Parag Mahanti ,
Julie Masow ,
Sloan Simpson ,
Aleix Prat ,
Alina Levchuk ,
American Society Of Clinical Oncology ,
European Society Of Medical Oncology ,
Twitter ,
Translational Research In Oncology ,
Novartis External Communications ,
Novartis ,
Head Of The Translational Genomics Group ,
Novartis Pharmaceuticals ,
Pfizer Inc ,
Virtual Scientific Program ,
University Of Barcelona ,
Novartis Institutes For Biomedical Research ,
Astex Pharmaceuticals ,
Drug Administration ,
European Commission ,
Novartis Oncology Communications ,
Novartis Us External Communications ,
Exchange Commission ,
Novartis Pharmaceuticals Corporation ,
Akershus University Hospital ,
Novartis Pharmaceuticals Corp ,
San Antonio Breast Cancer Symposium ,
Antonio Breast Cancer Symposium ,
Medical Oncology Department ,
Translational Genomics Group ,
Targeted Therapies ,
Solid Tumors ,
Clinical Oncology ,
Scientific Program ,
New England Journal ,
Novartis Institutes ,
Biomedical Research ,
Advanced Breast ,
Safety Information ,
Prescribing Information ,
European Society ,
Medical Oncology ,
Endocrine Therapy ,
American Society ,
Annual Meeting ,
Biomarker Analysis ,
Intrinsic Subtypes ,
Efficacy Across ,
Carolina Breast Cancer ,
Clin Oncol ,
Translational Research ,
Evaluate Efficacy ,
Ribociclib With Endocrine Therapy ,
Adjuvant Treatment ,
Patients With ,
Breast Cancer ,
Dharma ,
Kisqali ,
Data ,
Shows ,
Consistent ,
Verall ,
Survival ,
Benefit ,
Cross ,
Enomic ,
Linical ,
Subtypes ,
Interest ,
Ther2 ,
Metastatic ,
Breast ,
Dancer ,